Lichen China
LICN
3 hedge funds and large institutions have $165K invested in Lichen China in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
16,674% more capital invested
Capital invested by funds: $985 → $165K (+$164K)
200% more funds holding
Funds holding: 1 → 3 (+2)
1.03% more ownership
Funds ownership: 0% → 1.03% (+1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$500K |
| 2 |
VF
Virtu Financial
New York
|
+$117K |
| 3 |
CIAM
Caitong International Asset Management
Hong Kong
|
+$4 |
Top Sellers
LICN Hedge Fund Activity: Q2 2026 in Review
3 of the 8,331 institutional investors tracked by Wall St. Rank reported a position in Lichen China (LICN) for Q2 2026, worth a combined $165K — up 16,674% from $985 a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new LICN positions and 0 closed out — a net gain of 2 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $500K.
- 3 institutional investors held Lichen China (LICN) as of Q2 2026, up from 1 in Q1 2026.
- Funds reported $165K of Lichen China stock for Q2 2026, up 16,674% quarter-over-quarter.
- 2 funds opened new Lichen China positions in Q2 2026 and 0 closed out, a net change of +2 holders.
- The largest Lichen China buyer in Q2 2026 was UBS Group, an estimated $500K added.
Based on aggregated 13F filings for Q2 2026.